Rocket Lab Sinks as Neutron's Maiden Flight Slips to 2027 on Tank Flaw

Rocket Lab's flagship Neutron rocket will not reach orbit as soon as the company had hoped, and investors wasted little time repricing the stock on the news. A regulatory filing with the US Securities and Exchange Commission confirmed that the debut launch, previously pencilled in for the fourth quarter of 2026, has now been pushed into 2027. The disclosure, made via a Form 8-K, landed hard: the shares shed 7.5% during Wednesday's session to close at EUR 53.10, with Reuters noting that the announcement had already weighed on the stock in after-hours trading.

The setback deepened on Thursday, when the equity came under renewed pressure in European trading. The stock dropped 13% to EUR 46.05, extending a slide that has left the company nursing a double-digit decline and testing the conviction of its shareholder base.

A composite dome at the centre of the problem

At the heart of the delay is a manufacturing issue affecting the upper dome of the first stage's fuel tank. According to media reports, voids detected in the carbon-fibre composite structure forced engineers to redesign the component from scratch. Rocket Lab has said the difficulties have been identified and are being addressed, but the reworked hardware demands further revisions and testing, with those stress tests expected to run into the first quarter of 2027. Only once that phase concludes successfully does the company intend to set a fresh, concrete launch date.

The stakes extend well beyond a single rocket. Neutron is designed to carry substantially heavier payloads than the smaller Electron vehicle, which already flies regular commercial missions. Every month of slippage therefore delays Rocket Lab's entry into more lucrative payload segments and ties up additional capital while pushing future heavy-lift revenue further out.

Wall Street's stance: patience, with trimmed targets

Analysts had already staked out bullish positions before the latest disclosure. Barclays initiated coverage on 8 October with an Overweight rating and an $85 price target. TD Cowen reaffirmed its Buy recommendation on 9 October, though analyst Gautam Khanna trimmed his target to $90 from $120 as part of a broader sector preview, explicitly retaining his constructive view on the space company. Goldman Sachs, by contrast, keeps a neutral rating on the stock with a $75 target, down from $80 previously.

That split captures the tension now facing investors: the long-term commercial case for Neutron remains intact, but the timeline that underpins it has just grown longer. Should Rocket Lab execute against the revised schedule without further incidents, the current weakness could eventually look like an attractive entry point.

The risks that could turn a dip into a drift

Not every scenario is benign. Space projects are notoriously prone to cascading schedule failures, and if the 2027 stress tests on the redesigned components expose fresh weaknesses, another launch delay becomes a real possibility. Such a setback would bring direct cost overruns and widen the operational gap to established competitors.

The technical picture has also deteriorated. Following the declines, the stock now trades 66% below its 52-week high, a gap that speaks to how sensitive the market has become to slippage in core development programmes. If investor scepticism takes hold, the equity could remain stuck in a valuation trap for some time, and a failure to deliver the rocket on schedule would eventually weigh on revenue targets and the company's financial planning.

What to watch from here

The path through the coming quarters is now clearly marked. Provided market support holds and no further design flaws surface, attention will focus on production progress reports. A loss of confidence in the company's ability to build the first stage would invite further declines.

The next hard catalyst is already fixed: once manufacturing checks and test campaigns wrap up in the first quarter of 2027, Rocket Lab will present a new date for Neutron's maiden flight. Until that milestone arrives, the stock will demand patience — and a healthy appetite for risk — from those who stay on board.